MedTrace Logo

IL-6, IL-17 and IL-35 Levels in the Gingival Crevicular Fluid of Patients With Periodontitis and Healthy Controls

NCT05306860 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-03-05

No results posted yet for this study

Summary

Periodontitis is an inflammatory disease characterized by periodontal tissue destruction caused by bacterial infection. The immune response plays an important role in the progression of periodontitis. The disease process starts with periodontopathogens in dental plaque, and tissue destruction is mainly caused by the immune response of the host to the etiological microorganism and cytokine profile through various inflammatory cytokines. The cytokine response, which plays a critical role in the pathogenesis of periodontal disease, determines the progression of the disease.

Evaluation of the effects of IL-6, IL-17 and IL-35 levels in the gingival crevicular fluid on periodontal disease together with clinical parameters has been the basis of our study. This study consists of individuals with grad B-C stage III-IV periodontitis and healthy individuals, which is the subtitle of Periodontal and Periimplant Diseases and Conditions in the classification renewed in 2017.

It is aimed to examine the changes and possible correlations in IL-6, IL-17, IL-35 levels as a result of biochemical examination of the samples taken from the gingival crevicular fluid. In our study, according to the new classification of 2017, gingival crevicular fluid samples collected from individuals with grade B-C stage III-IV periodontal disease and healthy individuals under appropriate conditions and techniques were measured for IL-6, IL-17 and IL-35 by enzymatic immunosorbent test (ELISA). It aims to investigate the negative/positive correlations and compare the increases-decreases.

Conditions

  • Periodontitis

Interventions

OTHER

No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)

No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Emine Çifcibaşı, Assoc.Prof. · Istanbul University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2022-11-30
Completion
2023-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05306860 on ClinicalTrials.gov